Wageningen University and DNASTAR Extend Lasergene Site License Agreement
News Nov 24, 2009
DNASTAR and Wageningen University and Research centre in Wageningen, the Netherlands announced the signing of a broad site license agreement for the use of Lasergene® sequence analysis software developed by DNASTAR.
Under the terms of the site license, all researchers in the Department of Agrotechnology and Food Sciences will have unlimited use of the software for their sequence analysis projects. The site license will include the latest version of Lasergene, v8.1, which provides users with automated virtual MultiSite Gateway cloning capabilities, along with numerous other new features.
Lasergene, a comprehensive sequence analysis software program sold in more than 65 countries worldwide, provides users with tools to perform a wide range of DNA assembly, visualization and analysis operations on data generated by the conventional Sanger sequencing method as well as Next Generation platforms available from Roche 454, Illumina, ABI SOLiD and Helicos. It can also be used in a wide range of protein analysis applications. Additional Lasergene information and Free Trial versions of the software are available.
Bob Steinhauser, DNASTAR’s Director of Marketing stated, “Wageningen UR and DNASTAR have been working together for many years. This is the second department-wide site license for the use of our software at the University. We are extremely pleased that as the activities at the University have grown, DNASTAR has been able to grow with them. Lasergene’s novel features, broad applications base and constant updating with new Features, makes it an excellent sequence analysis platform choice to address present and future genomic research needs.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.